Immunocompromised Swiss Cohorts Based Trial Platform

NCT04805125 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

610

Enrollment

OTHER

Sponsor class

Conditions

Immunocompromised Patients

Interventions

BIOLOGICAL: Moderna COVID-19 Vaccine, mRNA-1273 (100 μg)
BIOLOGICAL: Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (30 µg)( Comirnaty®)

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]
[object Object]